MAIA BIOTECHNOLOGY INC (MAIA)

Company Profile

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 18 full-time employees. The company went IPO on 2022-07-28. The firm is focused on developing oncology drug candidates to improve and extend the lives of people with cancer. The Company’s pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers. The firm's THIO (6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is a telomere-targeting agent in clinical development. THIO is followed by Libtayo for the treatment of advanced non-small-cell lung cancer. The firm is advancing THIO in Phase II clinical study in Non-Small Cell Lung Cancer. The firm's second-generation program is engaged in discovering new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. The second-generation pipeline of potential telomere-targeting agents includes five compounds that have undergone in vitro inhibitory testing in five cancer models.

Company Info

MAIA BIOTECHNOLOGY INC

444 West Lake Street, Suite 1700, Suite 1700

Chicago ILLINOIS

P: 13124168592

Employees: 18

Website: https://maiabiotech.com/